Trial Profile
A Phase 1, Dose Escalation Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Mar 2024
Price :
$35
*
At a glance
- Drugs Evorpacept (Primary) ; Pembrolizumab (Primary) ; Rituximab (Primary) ; Trastuzumab (Primary) ; Cisplatin; Fluorouracil; Paclitaxel; Ramucirumab
- Indications Adenocarcinoma; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Head and neck cancer; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Acronyms ASPEN-01
- Sponsors ALX Oncology
- 21 Mar 2024 Planned End Date changed from 1 Feb 2024 to 1 Dec 2024.
- 20 Jul 2023 Planned End Date changed from 1 Feb 2023 to 1 Feb 2024.
- 01 Aug 2022 According to an ALX Oncology media release, based on results from this study the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to evorpacept, in combination with KEYTRUDA (pembrolizumab), for the first-line treatment of adult patients with PD-L1 positive advanced head and neck squamous cell carcinoma (HNSCC).